Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

Alison H.M. Reid, Gerhardt Attard, Daniel C. Danila, Nikhil Babu Oommen, David Olmos, Peter C. Fong, L. Rhoda Molife, Joanna Hunt, Christina Messiou, Christopher Parker, David Dearnaley, Joost F. Swennenhuis, Leon W.M.M. Terstappen, Gloria Lee, Thian Kheoh, Arturo Molina, Charles J. Ryan, Eric Small, Howard I. Scher, Johann S. de Bono

Research output: Contribution to journalArticleAcademicpeer-review

347 Citations (Scopus)
56 Downloads (Pure)

Abstract

Purpose: The principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC).

Patients and Methods: In this multicenter, two-stage, phase II study, abiraterone acetate 1,000 mg was administered once daily continuously. The primary end point was achievement of a prostate-specific antigen (PSA) decline of ≥ 50% in at least seven of 35 patients. Per an attained phase II design, more than 35 patients could be enrolled if the primary end point was met. Secondary objectives included: PSA declines of ≥ 30% and ≥ 90%; rate of RECIST (Response Evaluation Criteria in Solid Tumors) responses and duration on study; time to PSA progression; safety and tolerability; and circulating tumor cell (CTC) enumeration.

Results: Docetaxel-treated patients with CRPC (N = 47) were enrolled. PSA declines of ≥ 30%, ≥ 50% and ≥ 90% were seen in 68% (32 of 47), 51% (24 of 47), and 15% (seven of 47) of patients, respectively. Partial responses (by RECIST) were reported in eight (27%) of 30 patients with measurable disease. Median time to PSA progression was 169 days (95% CI, 113 to 281 days). The median number of weeks on study was 24, and 12 (25.5%) of 47 patients remained on study ≥ 48 weeks. CTCs were enumerated in 34 patients; 27 (79%) of 34 patients had at least five CTCs at baseline. Eleven (41%) of 27 patients had a decline from at least five to less than 5 CTCs, and 18 (67%) of 27 had a ≥ 30% decline in CTCs after starting treatment with abiraterone acetate. Abiraterone acetate was well tolerated.

Conclusion: Abiraterone acetate has significant antitumor activity in post-docetaxel patients with CRPC. Randomized, phase III trials of abiraterone acetate are underway to define the future role of this agent.
Original languageEnglish
Pages (from-to)1489-1495
JournalJournal of clinical oncology
Volume28
Issue number9
DOIs
Publication statusPublished - 2010

Keywords

  • METIS-269463

Fingerprint

Dive into the research topics of 'Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate'. Together they form a unique fingerprint.

Cite this